ImageneBio, Inc. (NASDAQ:IMA) Receives $26.50 Average PT from Analysts

Shares of ImageneBio, Inc. (NASDAQ:IMA) have earned a consensus rating of “Hold” from the five analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.50.

Several equities research analysts have recently weighed in on the company. Weiss Ratings began coverage on ImageneBio in a report on Wednesday, October 22nd. They issued a “sell (e-)” rating on the stock. Wall Street Zen downgraded ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Wedbush downgraded shares of ImageneBio from a “neutral” rating to an “underperform” rating in a report on Tuesday, November 25th. Leerink Partners initiated coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Leerink Partnrs upgraded ImageneBio to a “strong-buy” rating in a report on Friday, October 24th.

Hedge Funds Weigh In On ImageneBio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC acquired a new position in ImageneBio during the third quarter valued at $104,000. NewEdge Advisors LLC acquired a new position in ImageneBio in the 3rd quarter valued at approximately $106,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of ImageneBio during the third quarter worth $144,000. Aldebaran Capital LLC purchased a new stake in shares of ImageneBio during the 3rd quarter worth about $159,000. Finally, Squarepoint Ops LLC bought a new stake in shares of ImageneBio in the 3rd quarter valued at approximately $197,000. 75.00% of the stock is owned by institutional investors.

ImageneBio Price Performance

Shares of IMA stock opened at $6.17 on Friday. The stock has a market capitalization of $68.98 million, a PE ratio of -0.76 and a beta of 0.44. The business has a 50-day moving average of $7.57 and a 200 day moving average of $11.63. ImageneBio has a 1-year low of $6.11 and a 1-year high of $23.28.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($1.44). Analysts anticipate that ImageneBio will post -0.91 EPS for the current year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.